Related Experiment Video
Updated: May 10, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Laboratory assessment of rivaroxaban: a review
Meyer Michel Samama1, Geneviève Contant, Theodore E Spiro
1Hôtel-Dieu University Hospital, 1 place du Paris Notre-Dame, Paris 75004, 4ème, Paris, France. meyermichel.samama@biomnis.com.
Abstract:
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases thrombin generation. Based on the results of phase III clinical trials, rivaroxaban, a direct Factor Xa inhibitor, has been approved in many countries for the management of several thromboembolic disorders. Owing to its predictable pharmacokinetic and pharmacodynamic characteristics, fixed-dose regimens are used without the need for routine coagulation monitoring. In situations where assessment of rivaroxaban exposure may be helpful, anti-Factor Xa chromogenic assays (in tandem with standard calibration curves generated with the use of rivaroxaban calibrators and controls) could be used. It is important to note that test results will be affected by the timing of blood sampling after rivaroxaban intake. In addition, the anti-Factor Xa method measures the drug concentration and not the intensity of the drug's anticoagulant activity, and a higher than expected rivaroxaban plasma level does not necessarily indicate an increased risk of bleeding complications. Therefore, clinicians need to consider test results in relation to the pharmacokinetics of rivaroxaban and other patient risk factors associated with bleeding.
Insights
Rivaroxaban, a direct Factor Xa inhibitor, effectively manages thromboembolic disorders with fixed doses. Anti-Factor Xa assays can measure drug levels when needed, but results require careful interpretation alongside patient factors.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Thromboembolic disorders necessitate effective anticoagulation.
- Targeting specific coagulation enzymes like Factor Xa offers a therapeutic strategy.
- Rivaroxaban, a direct Factor Xa inhibitor, has demonstrated efficacy in clinical trials.
Purpose of the Study:
- To review the role and application of rivaroxaban in managing thromboembolic disorders.
- To discuss the utility and interpretation of anti-Factor Xa assays for assessing rivaroxaban exposure.
- To highlight considerations for clinicians when interpreting assay results.
Main Methods:
- Review of phase III clinical trial data for rivaroxaban.
- Discussion of pharmacokinetic and pharmacodynamic properties of rivaroxaban.
- Explanation of anti-Factor Xa chromogenic assays and their calibration.
Main Results:
- Rivaroxaban is approved for managing several thromboembolic disorders.
- Fixed-dose regimens are generally used without routine coagulation monitoring.
- Anti-Factor Xa assays can quantify rivaroxaban levels, aiding exposure assessment.
Conclusions:
- Rivaroxaban offers a predictable anticoagulant profile suitable for fixed dosing.
- Interpretation of anti-Factor Xa assay results requires consideration of sampling time and patient-specific bleeding risks.
- Assays measure drug concentration, not anticoagulant activity intensity, necessitating clinical correlation.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
